We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

32 hedge funds and large institutions have $18.1M invested in Catalyst Pharmaceutical in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more call options, than puts

Call options by funds: $12K | Put options by funds: $3K

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

28% more funds holding

Funds holding: 25 → 32 (+7)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

26% less capital invested

Capital invested by funds: $24.4M → $18.1M (-$6.28M)

Holders
32
Holders Change
+7
Holders Change %
+28%
% of All Funds
0.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
3
Reduced
3
Closed
8
Calls
$12K
Puts
$3K
Net Calls
+$9K
Net Calls Change
+$9K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$485K
2
ZIM
Zacks Investment Management
Illinois
+$314K
3
AQR Capital Management
AQR Capital Management
Connecticut
+$303K
4
State Street
State Street
Massachusetts
+$95.4K
5
CPA
Cowen Prime Advisors
New York
+$60.6K

Top Sellers

Rank Fund Capital Flow
1
EI
EAM Investors
California
-$1.36M
2
SC
Sophrosyne Capital
New York
-$732K
3
Renaissance Technologies
Renaissance Technologies
New York
-$422K
4
Deutsche Bank
Deutsche Bank
Germany
-$144K
5
VKH
Virtu KCG Holdings
New York
-$95K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$6.35M -$60.7K -30,040 -0.9%
O
2
OrbiMed
New York
$3.69M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$2.8M +$485K +239,800 +20%
OM
4
Opaleye Management
Massachusetts
$2.64M +$2.74M +1,353,900 New
GTC
5
Ghost Tree Capital
New York
$341K +$354K +175,000 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$322K – – –
ZIM
7
Zacks Investment Management
Illinois
$303K +$314K +155,424 New
AQR Capital Management
8
AQR Capital Management
Connecticut
$292K +$303K +149,682 New
TCM
9
Tanaka Capital Management
New York
$251K – – –
Bank of New York Mellon
10
Bank of New York Mellon
New York
$198K – – –
Northern Trust
11
Northern Trust
Illinois
$129K +$20.5K +10,158 +18%
State Street
12
State Street
Massachusetts
$92K +$95.4K +47,200 New
California Public Employees Retirement System
13
California Public Employees Retirement System
California
$91K – – –
Dimensional Fund Advisors
14
Dimensional Fund Advisors
Texas
$91K – – –
Jane Street
15
Jane Street
New York
$83K -$11.5K -5,688 -12%
CPA
16
Cowen Prime Advisors
New York
$59K +$60.6K +30,000 New
FANJ
17
Financial Architects (New Jersey)
New Jersey
$59K +$60.6K +30,000 New
CAN
18
Cetera Advisor Networks
California
$56K – – –
Citadel Advisors
19
Citadel Advisors
Florida
$38K +$39.4K +19,470 New
TRCT
20
Tower Research Capital (TRC)
New York
$32K +$33.4K +16,540 New
GC
21
Guggenheim Capital
Illinois
$29K +$1.81K +895 +6%
Bank of America
22
Bank of America
North Carolina
$27K -$17.3K -8,553 -39%
Group One Trading
23
Group One Trading
Illinois
$25K +$26.1K +12,900 New
TAM
24
Telluride Asset Management
Minnesota
$22K +$23.1K +11,446 New
Janney Montgomery Scott
25
Janney Montgomery Scott
Pennsylvania
$19.5K +$20.2K +10,000 New
1
2

CPRX Hedge Fund Activity: Q4 2013 in Review

32 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q4 2013, worth a combined $18.1M — down 26% from $24.4M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new CPRX positions and 8 closed out — a net gain of 7 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $485K. The largest seller was EAM Investors, exiting entirely with an estimated $1.36M sold.

  • 32 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q4 2013, up from 25 in Q3 2013.
  • Funds reported $18.1M of Catalyst Pharmaceutical stock for Q4 2013, down 26% quarter-over-quarter.
  • 15 funds opened new Catalyst Pharmaceutical positions in Q4 2013 and 8 closed out, a net change of +7 holders.
  • The largest Catalyst Pharmaceutical buyer in Q4 2013 was Vanguard Group, an estimated $485K added.
  • The largest Catalyst Pharmaceutical seller in Q4 2013 was EAM Investors, an estimated $1.36M sold.

Based on aggregated 13F filings for Q4 2013.